Analysis Of The Expression Of FPN1 And DMT1 In Hepatocellular Carcinoma And Its Relationship With Drug Therapy Efficacy

Objective:This study is a retrospective study to detect Ferroportin 1(FPN1)and divalent metal transporter 1(DMT1)expression in HCC and analysis the relationship of among the targeted protein expression,clinical pathological characteristics,and therapeutic effect,in order to illustrate the mechanism of drug resistance in HCC and lay the foundation for individual treatment with drug.Methods:HCC patients were collected with paraffin-embeded of carcinomar tissue and para-carcinoma tissue,clinical and pathological data from January 1,2010 to December 31,2015 at Affiliated Tumor Hospital of Guangxi Medical University,who undertook chemotherapy or sorafenib after post-operate recurrence.FPN1 and DMT1 were detected by immunohistochemical method to analyse the relationship of FPN1 and DMT1 expression and clinical and pathological characteristcs.PFS and OS were followed up by medical record review and telephone to analyse the effects of FPN1 and DMT1 to PFS and OS.Results:The positive expression rate of FPN1 and DMT1 were 63.96%and 81.48%in HCC tissue,and 90%and 45%in paracancerous tissue.There existed statistically significant correlation between the expression level of FPN1 and DMT1 and the tumor differentiation(P<0.05).In FPN1 positive patients,DCR was 41.2%,median PFS was 6.7 month,median OS was 15.7 month and 10.0%,1.8 month and 8 month in FPN1 negative patients.In DMT1 positive patients,DCR was 18.2%,median PFS was 3.2 month,median OS was 9.3 month and 60%,18.6 month and 35.9 month in DMT1 negative patients.The difference between PFS and OS were statistically significant in both FPN1 and DMT1 expression(P<0.05)and no statistically significant difference was found in DCR(P>0.05)。Conclusions:1.The expression rate of FPN1 in HCC was lower,and that of DMT1 was higher,which were associated with the differentiation of the tumor.2.The expression of FPN1 and DMT1 had nothing to do with DCR of the advanced HCC patients undertaking chemotherapy or targeted medicine.3.Patients of FPN1 positive had longer PFS and OS than those of FPN1 negative.4.Patients of DMT1 negative had longer PFS and OS than those of DMT1 positive.